| Nov 21 |
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
|
| Nov 18 |
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering
|
| Nov 15 |
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
|
| Nov 13 |
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants
|
| Aug 13 |
Virpax Pharmaceuticals GAAP EPS of -$1.75
|
| Aug 13 |
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
|
| Jul 29 |
Virpax Pharmaceuticals files to sell common stock, warrants
|
| Jul 24 |
Virpax regains compliance with Nasdaq minimum bid price
|
| Jul 24 |
Virpax Regains Compliance with Nasdaq Minimum Bid Price
|
| Jul 12 |
Latest Cannabis Hires And Board Changes, Here's What You Need To Know
|
